Jennifer Wiebracht is a process development scientist II at KBI Biopharma in Boulder, CO. KBI is a global CDMO that supports clients across the biopharmaceutical industry, from early proof-of-concept and first-in-human (FIH) studies to late-stage process characterization and commercial readiness. Jennifer specializes in downstream purification of microbially expressed recombinant proteins and routinely adapts workflows to meet evolving technical and regulatory needs across development stages. She frequently works with the KR2i TFF system to support flexible ultrafiltration/diafiltration (UF/DF) operations, accelerate timelines, and troubleshoot scale-up challenges.

Xiaojun Liu, PhD is an accomplished bioprocess leader with over 20 years of experience in gene therapy, specializing in viral vector (AAV/LV) development and CMC strategy. As the director at ReciBioPharm, a Recipharm company, he manages a cross-functional team in AAV/LV process development, including upstream, downstream, and analytical development, while overseeing tech transfers to cGMP manufacturing for IND-enabling studies. He has advanced multiple gene therapy programs targeting liver, ocular, and cardiovascular conditions. Liu has published over 70 papers and patents and received over 8,300 citations, showcasing his strong track record from his previous roles at EdiGene Biotech USA and Luye Pharma. He trained at Harvard Medical School and is currently an associate editor for molecular biotechnology and a member of ASGCT’s Viral Gene Transfer Vectors Committee. Liu holds a doctoral degree in genetics from Fudan University and a bachelor's degree from Sichuan University.